Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report
Third-generation tyrosine kinase inhibitors are effective treatment of EGFR-mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There is no standard o...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364325000232 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849734151348944896 |
|---|---|
| author | Aditi Singh, MBBS, MPH Arthi Sridhar, MBBS Aastha Poddar, MBBS Anastasios Dimou, MD Kaushal Parikh, MBBS Mohamed Shanshal, MD Anna Schwecke, APRN, CNP, MS Nicole Moffett, APRN, CNP, MSN Manish R. Patel, DO Aaron S. Mansfield, MD Konstantinos Leventakos, MD, PhD |
| author_facet | Aditi Singh, MBBS, MPH Arthi Sridhar, MBBS Aastha Poddar, MBBS Anastasios Dimou, MD Kaushal Parikh, MBBS Mohamed Shanshal, MD Anna Schwecke, APRN, CNP, MS Nicole Moffett, APRN, CNP, MSN Manish R. Patel, DO Aaron S. Mansfield, MD Konstantinos Leventakos, MD, PhD |
| author_sort | Aditi Singh, MBBS, MPH |
| collection | DOAJ |
| description | Third-generation tyrosine kinase inhibitors are effective treatment of EGFR-mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There is no standard of care for the management of transformed SCLC. Given the rarity of transformed SCLC, it is important to study treatment options that are safe and effective for this disease. In this case series, three patients received treatment with lurbinectedin plus osimertinib after transformation to SCLC. In our limited experience, the combination was found to be safe. |
| format | Article |
| id | doaj-art-b19a2235edb043bca0ae5ba14dddc8f6 |
| institution | DOAJ |
| issn | 2666-3643 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj-art-b19a2235edb043bca0ae5ba14dddc8f62025-08-20T03:07:51ZengElsevierJTO Clinical and Research Reports2666-36432025-06-016610080710.1016/j.jtocrr.2025.100807Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief ReportAditi Singh, MBBS, MPH0Arthi Sridhar, MBBS1Aastha Poddar, MBBS2Anastasios Dimou, MD3Kaushal Parikh, MBBS4Mohamed Shanshal, MD5Anna Schwecke, APRN, CNP, MS6Nicole Moffett, APRN, CNP, MSN7Manish R. Patel, DO8Aaron S. Mansfield, MD9Konstantinos Leventakos, MD, PhD10Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota; Corresponding author. Address for correspondence: Aditi Singh, MBBS, MPH, Department of Hematology Oncology, 1 Veterans Drive, Minneapolis, Minnesota.Department of Medical Oncology, Mayo Clinic, Rochester, MinnesotaDepartment of Health Sciences Research, Mayo Clinic, College of Medicine, Rochester, MinnesotaDepartment of Medical Oncology, Mayo Clinic, Rochester, MinnesotaDepartment of Medical Oncology, Mayo Clinic, Rochester, MinnesotaDepartment of Medical Oncology, Mayo Clinic, Rochester, MinnesotaDepartment of Medical Oncology, Mayo Clinic, Rochester, MinnesotaDepartment of Medical Oncology, Mayo Clinic, Rochester, MinnesotaDivision of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MinnesotaDepartment of Medical Oncology, Mayo Clinic, Rochester, MinnesotaDepartment of Medical Oncology, Mayo Clinic, Rochester, MinnesotaThird-generation tyrosine kinase inhibitors are effective treatment of EGFR-mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There is no standard of care for the management of transformed SCLC. Given the rarity of transformed SCLC, it is important to study treatment options that are safe and effective for this disease. In this case series, three patients received treatment with lurbinectedin plus osimertinib after transformation to SCLC. In our limited experience, the combination was found to be safe.http://www.sciencedirect.com/science/article/pii/S2666364325000232NSCLCSCLCEGFROsimertinibLurbinectedinTranformed SCLC |
| spellingShingle | Aditi Singh, MBBS, MPH Arthi Sridhar, MBBS Aastha Poddar, MBBS Anastasios Dimou, MD Kaushal Parikh, MBBS Mohamed Shanshal, MD Anna Schwecke, APRN, CNP, MS Nicole Moffett, APRN, CNP, MSN Manish R. Patel, DO Aaron S. Mansfield, MD Konstantinos Leventakos, MD, PhD Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report JTO Clinical and Research Reports NSCLC SCLC EGFR Osimertinib Lurbinectedin Tranformed SCLC |
| title | Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report |
| title_full | Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report |
| title_fullStr | Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report |
| title_full_unstemmed | Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report |
| title_short | Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report |
| title_sort | combination of lurbinectedin and osimertinib for treatment of egfr mutated transformed sclc a brief report |
| topic | NSCLC SCLC EGFR Osimertinib Lurbinectedin Tranformed SCLC |
| url | http://www.sciencedirect.com/science/article/pii/S2666364325000232 |
| work_keys_str_mv | AT aditisinghmbbsmph combinationoflurbinectedinandosimertinibfortreatmentofegfrmutatedtransformedsclcabriefreport AT arthisridharmbbs combinationoflurbinectedinandosimertinibfortreatmentofegfrmutatedtransformedsclcabriefreport AT aasthapoddarmbbs combinationoflurbinectedinandosimertinibfortreatmentofegfrmutatedtransformedsclcabriefreport AT anastasiosdimoumd combinationoflurbinectedinandosimertinibfortreatmentofegfrmutatedtransformedsclcabriefreport AT kaushalparikhmbbs combinationoflurbinectedinandosimertinibfortreatmentofegfrmutatedtransformedsclcabriefreport AT mohamedshanshalmd combinationoflurbinectedinandosimertinibfortreatmentofegfrmutatedtransformedsclcabriefreport AT annaschweckeaprncnpms combinationoflurbinectedinandosimertinibfortreatmentofegfrmutatedtransformedsclcabriefreport AT nicolemoffettaprncnpmsn combinationoflurbinectedinandosimertinibfortreatmentofegfrmutatedtransformedsclcabriefreport AT manishrpateldo combinationoflurbinectedinandosimertinibfortreatmentofegfrmutatedtransformedsclcabriefreport AT aaronsmansfieldmd combinationoflurbinectedinandosimertinibfortreatmentofegfrmutatedtransformedsclcabriefreport AT konstantinosleventakosmdphd combinationoflurbinectedinandosimertinibfortreatmentofegfrmutatedtransformedsclcabriefreport |